{"id":58452,"date":"2025-09-23T10:27:48","date_gmt":"2025-09-23T04:57:48","guid":{"rendered":"https:\/\/newswiredelhi.com\/index.php\/2025\/09\/23\/virulina-patent-awarded-polyherbal-breakthrough-for-viral-respiratory-infection-and-immunomodulatory-conditions\/"},"modified":"2025-09-23T10:27:48","modified_gmt":"2025-09-23T04:57:48","slug":"virulina-patent-awarded-polyherbal-breakthrough-for-viral-respiratory-infection-and-immunomodulatory-conditions","status":"publish","type":"post","link":"https:\/\/newswiredelhi.com\/index.php\/2025\/09\/23\/virulina-patent-awarded-polyherbal-breakthrough-for-viral-respiratory-infection-and-immunomodulatory-conditions\/","title":{"rendered":"Virulina: Patent-Awarded Polyherbal Breakthrough for Viral Respiratory Infection and Immunomodulatory Conditions"},"content":{"rendered":"
\n

New Delhi [India], September 22: <\/strong>Viral respiratory infections (VRIs) have long been a persistent challenge for global healthcare. From seasonal flu-like illnesses to more severe viral conditions, these infections often affect millions each year, causing breathlessness, persistent cough, fatigue, and in many cases, long-term respiratory damage. Despite advances in modern medicine, treatment options remain limited, with many patients relying only on symptomatic relief. Unfortunately, overuse of antibiotics\u2014despite their ineffectiveness against viruses\u2014has worsened the crisis of antimicrobial resistance.<\/p>\n

This growing medical gap called for a safe, evidence-based, and holistic approach. Rising to the challenge,\u00a0Natural Solutions and Neutraceuticals Pvt Ltd (NSNPL<\/a>) , a registered company in Mumbai, Maharashtra, developed\u00a0Virulina\u00ae<\/strong><\/a>, a patent-awarded polyherbal formulation designed to combat VRIs with a unique triple action\u2014immunomodulatory, anti-inflammatory, and antiviral properties in one formulation.<\/p>\n

What makes Virulina\u00ae truly exceptional is not only its scientific validation\u2014including<\/p>\n

preclinical, toxicology, and clinical studies, and CSIR-backed antiviral research at the Regional Centre of Biotechnology, Faridabad\u2014but also the passion and perseverance of its creators: Dr. Anil Kumar Sharma (BNYS, MD AM), Dr. Sandeep Arora (Ph.D., Pharmaceutical Sciences), and Dr. Dishya Sewda (BAMS).<\/p>\n

The Motivation: A Patient-Centric Mission<\/strong><\/h2>\n

The story of Virulina\u00ae is rooted in compassion and necessity. As Dr. Sharma recalls, patients suffering from viral respiratory complications often had no effective solutions. Families were helpless, physicians were constrained by limited treatment choices, and recovery was slow.<\/p>\n

\u201cWe developed Virulina out of a sense of duty,\u201d Dr. Sharma shares. \u201cThe suffering we saw inspired us to create something that could truly change outcomes. We had neither large financial reserves nor pharmaceutical backing\u2014what we had was passion, knowledge, and the determination to serve patients.\u201d<\/p>\n

This motivation sparked a research journey that would blend traditional Ayurvedic wisdom with modern pharmacology, bridging two worlds to create a product capable of addressing an unmet global health need.<\/p>\n

The Science Behind Virulina\u00ae<\/strong><\/h2>\n

At its core, Virulina\u00ae is not just another herbal supplement\u2014it is a scientifically validated phytopharmaceutical with a unique multi-target mechanism:<\/p>\n

Immunomodulatory Action:<\/strong>
\nVirulina\u00ae enhances both innate and adaptive immune responses. It stimulates leukocyte migration, supports lymphocyte proliferation, and improves the phagocytic function of polymorphonuclear cells\u2014helping the body respond effectively to viral invasions.<\/p>\n

Anti-Inflammatory Properties:<\/strong>
\nIn viral infections, hyperinflammation often causes more harm than the virus itself. Virulina\u00ae downregulates pro-inflammatory mediators such as nitric oxide, cytokines, chemokines, and growth factors. This mechanism helps reduce airway inflammation, prevent tissue damage, and maintain healthy respiratory function.<\/p>\n

Antiviral Activity:<\/strong>
\nPerhaps most significantly, Virulina\u00ae interferes with viral RNA replication by targeting RNA polymerase\u2014an enzyme crucial for viral survival. This reduces viral load and promotes faster recovery.<\/p>\n

Mucolytic & Fibrinolytic Benefits:<\/strong>
\nBeyond its core triple action, Virulina\u00ae supports airway clearance, reduces mucus viscosity, and prevents clot-related complications, ensuring comprehensive respiratory care.<\/p>\n

This integrative mechanism is what makes Virulina\u00ae stand apart from symptomatic treatments, offering a complete respiratory defense system.<\/p>\n

Immunity, Infections & Sudden Cardiac Arrest<\/strong><\/h2>\n

Emerging evidence highlights that immune modulation plays a vital role not only in fighting infections but also in maintaining heart health. While sudden cardiac arrest cannot be directly linked to any single factor such as vaccination, it is increasingly recognized that the after-effects of viral infections and immune challenges may influence cardiovascular function. By strengthening and balancing immune responses, formulations like Virulina\u00ae may contribute indirectly to resilience\u2014not only against respiratory complications but also in supporting overall systemic health.<\/p>\n

From Struggles to Recognition<\/strong><\/h2>\n

The journey of Virulina\u00ae was not without obstacles. Conducting multi-stage research\u2014preclinical, toxicology, clinical validation, and CSIR antiviral studies\u2014required immense financial investment and scientific rigor.<\/p>\n

\u201cCollaborating pharmaceutical sciences with natural solutions is never easy,\u201d Dr. Arora notes. \u201cEach stage demanded resources we did not have. But our commitment kept us moving forward. Even when promoting the product and creating awareness posed new challenges, we did not stop.\u201d<\/p>\n

This perseverance, however, yielded remarkable recognition:<\/p>\n